Nkarta, Inc. Share Price

Equities

NKTX

US65487U1088

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 01:14:38 18/06/2024 am IST 5-day change 1st Jan Change
5.455 USD -9.23% Intraday chart for Nkarta, Inc. -16.79% -16.67%
Sales 2024 * - Sales 2025 * - Capitalization 42Cr 3.54TCr
Net income 2024 * -12Cr -985.65Cr Net income 2025 * -14Cr -1.17TCr EV / Sales 2024 * -
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * -
P/E ratio 2024 *
-2.99 x
P/E ratio 2025 *
-2.69 x
Employees 150
Yield 2024 *
-
Yield 2025 *
-
Free-Float 94.83%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Nkarta, Inc.

1 day-8.99%
1 week-16.79%
Current month-19.00%
1 month-15.77%
3 months-51.75%
6 months+76.28%
Current year-16.67%
More quotes
1 week
5.45
Extreme 5.45
6.88
1 month
5.45
Extreme 5.45
7.39
Current year
5.37
Extreme 5.3717
16.24
1 year
1.28
Extreme 1.28
16.24
3 years
1.28
Extreme 1.28
40.64
5 years
1.28
Extreme 1.28
79.16
10 years
1.28
Extreme 1.28
79.16
More quotes
Managers TitleAgeSince
Chief Executive Officer 64 01/18/01
Director of Finance/CFO 39 05/23/05
Chief Tech/Sci/R&D Officer 61 01/16/01
Members of the board TitleAgeSince
Director/Board Member 61 27/20/27
Chief Executive Officer 64 01/18/01
Chairman 45 01/15/01
More insiders
Date Price Change Volume
18/24/18 5.5 -8.49% 455 429
14/24/14 6.01 -3.53% 467,294
13/24/13 6.23 -1.42% 487,533
12/24/12 6.32 -2.77% 413,428
11/24/11 6.5 -1.66% 348,514

Delayed Quote Nasdaq, June 18, 2024 at 12:59 am IST

More quotes
Nkarta, Inc. is a clinical-stage biopharmaceutical company advancing the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies for the treatment of patients with autoimmune diseases or hematologic malignancies. It is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. Both product candidates enable an on-demand, off-the-shelf approach involving scaled manufacturing to broaden patient access. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies. Its NKX019 oncology program is based on the potential to treat a variety of B-cell malignancies by targeting the CD19 antigen that is reliably expressed on these types of cancerous cells. Its NKX101 program is designed to enhance the power of innate NK cell biology to detect and kill cancerous cells.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
6.01 USD
Average target price
19.29 USD
Spread / Average Target
+220.89%
Consensus